FSH combined with letrozole for ovarian stimulation

Live birth rate per embryo transfer trended higher in the low-dose FSH group (9/15, 60%) compared with the high-dose group (2/11, 18%, P=0.051), and ROC curve analysis validated 150 IU as the optimal

Effect: adverse; LBR 2/11 (18%) HD vs 9/15 (60%) LD

Live birth rate per embryo transfer trended higher in the low-dose FSH group (9/15, 60%) compared with the high-dose group (2/11, 18%, P=0.051), and ROC curve analysis validated 150 IU as the optimal

Effect: adverse; LBR 2/11 (18%) HD vs 9/15 (60%) LD

Live birth rate per embryo transfer trended higher in the low-dose FSH group (9/15, 60%) compared with the high-dose group (2/11, 18%, P=0.051), and ROC curve analysis validated 150 IU as the optimal

Effect: adverse; LBR 2/11 (18%) HD vs 9/15 (60%) LD

Live birth rate per embryo transfer trended higher in the low-dose FSH group (9/15, 60%) compared with the high-dose group (2/11, 18%, P=0.051), and ROC curve analysis validated 150 IU as the optimal

Effect: adverse; LBR 2/11 (18%) HD vs 9/15 (60%) LD

Live birth rate per embryo transfer trended higher in the low-dose FSH group (9/15, 60%) compared with the high-dose group (2/11, 18%, P=0.051), and ROC curve analysis validated 150 IU as the optimal

Effect: adverse; LBR 2/11 (18%) HD vs 9/15 (60%) LD

Live birth rate per embryo transfer trended higher in the low-dose FSH group (9/15, 60%) compared with the high-dose group (2/11, 18%, P=0.051), and ROC curve analysis validated 150 IU as the optimal

Effect: adverse; LBR 2/11 (18%) HD vs 9/15 (60%) LD

Live birth rate per embryo transfer trended higher in the low-dose FSH group (9/15, 60%) compared with the high-dose group (2/11, 18%, P=0.051), and ROC curve analysis validated 150 IU as the optimal

Effect: adverse; LBR 2/11 (18%) HD vs 9/15 (60%) LD

Live birth rate per embryo transfer trended higher in the low-dose FSH group (9/15, 60%) compared with the high-dose group (2/11, 18%, P=0.051), and ROC curve analysis validated 150 IU as the optimal

Effect: adverse; LBR 2/11 (18%) HD vs 9/15 (60%) LD

Live birth rate per embryo transfer trended higher in the low-dose FSH group (9/15, 60%) compared with the high-dose group (2/11, 18%, P=0.051), and ROC curve analysis validated 150 IU as the optimal

Effect: adverse; LBR 2/11 (18%) HD vs 9/15 (60%) LD

Live birth rate per embryo transfer trended higher in the low-dose FSH group (9/15, 60%) compared with the high-dose group (2/11, 18%, P=0.051), and ROC curve analysis validated 150 IU as the optimal

Effect: adverse; LBR 2/11 (18%) HD vs 9/15 (60%) LD

Live birth rate per embryo transfer trended higher in the low-dose FSH group (9/15, 60%) compared with the high-dose group (2/11, 18%, P=0.051), and ROC curve analysis validated 150 IU as the optimal

Effect: adverse; LBR 2/11 (18%) HD vs 9/15 (60%) LD

Live birth rate per embryo transfer trended higher in the low-dose FSH group (9/15, 60%) compared with the high-dose group (2/11, 18%, P=0.051), and ROC curve analysis validated 150 IU as the optimal

Effect: adverse; LBR 2/11 (18%) HD vs 9/15 (60%) LD

Live birth rate per embryo transfer trended higher in the low-dose FSH group (9/15, 60%) compared with the high-dose group (2/11, 18%, P=0.051), and ROC curve analysis validated 150 IU as the optimal

Effect: adverse; LBR 2/11 (18%) HD vs 9/15 (60%) LD

Live birth rate per embryo transfer trended higher in the low-dose FSH group (9/15, 60%) compared with the high-dose group (2/11, 18%, P=0.051), and ROC curve analysis validated 150 IU as the optimal

Effect: adverse; LBR 2/11 (18%) HD vs 9/15 (60%) LD

Live birth rate per embryo transfer trended higher in the low-dose FSH group (9/15, 60%) compared with the high-dose group (2/11, 18%, P=0.051), and ROC curve analysis validated 150 IU as the optimal

Effect: adverse; LBR 2/11 (18%) HD vs 9/15 (60%) LD

Live birth rate per embryo transfer trended higher in the low-dose FSH group (9/15, 60%) compared with the high-dose group (2/11, 18%, P=0.051), and ROC curve analysis validated 150 IU as the optimal

Effect: adverse; LBR 2/11 (18%) HD vs 9/15 (60%) LD

Live birth rate per embryo transfer trended higher in the low-dose FSH group (9/15, 60%) compared with the high-dose group (2/11, 18%, P=0.051), and ROC curve analysis validated 150 IU as the optimal

Effect: adverse; LBR 2/11 (18%) HD vs 9/15 (60%) LD

Live birth rate per embryo transfer trended higher in the low-dose FSH group (9/15, 60%) compared with the high-dose group (2/11, 18%, P=0.051), and ROC curve analysis validated 150 IU as the optimal

Effect: adverse; LBR 2/11 (18%) HD vs 9/15 (60%) LD

Live birth rate per embryo transfer trended higher in the low-dose FSH group (9/15, 60%) compared with the high-dose group (2/11, 18%, P=0.051), and ROC curve analysis validated 150 IU as the optimal

Effect: adverse; LBR 2/11 (18%) HD vs 9/15 (60%) LD

Live birth rate per embryo transfer trended higher in the low-dose FSH group (9/15, 60%) compared with the high-dose group (2/11, 18%, P=0.051), and ROC curve analysis validated 150 IU as the optimal

Effect: adverse; LBR 2/11 (18%) HD vs 9/15 (60%) LD

Live birth rate per embryo transfer trended higher in the low-dose FSH group (9/15, 60%) compared with the high-dose group (2/11, 18%, P=0.051), and ROC curve analysis validated 150 IU as the optimal

Effect: adverse; LBR 2/11 (18%) HD vs 9/15 (60%) LD

Live birth rate per embryo transfer trended higher in the low-dose FSH group (9/15, 60%) compared with the high-dose group (2/11, 18%, P=0.051), and ROC curve analysis validated 150 IU as the optimal

Effect: adverse; LBR 2/11 (18%) HD vs 9/15 (60%) LD

Live birth rate per embryo transfer trended higher in the low-dose FSH group (9/15, 60%) compared with the high-dose group (2/11, 18%, P=0.051), and ROC curve analysis validated 150 IU as the optimal

Effect: adverse; LBR 2/11 (18%) HD vs 9/15 (60%) LD

Live birth rate per embryo transfer trended higher in the low-dose FSH group (9/15, 60%) compared with the high-dose group (2/11, 18%, P=0.051), and ROC curve analysis validated 150 IU as the optimal

Effect: adverse; LBR 2/11 (18%) HD vs 9/15 (60%) LD

Live birth rate per embryo transfer trended higher in the low-dose FSH group (9/15, 60%) compared with the high-dose group (2/11, 18%, P=0.051), and ROC curve analysis validated 150 IU as the optimal

Effect: adverse; LBR 2/11 (18%) HD vs 9/15 (60%) LD

Live birth rate per embryo transfer trended higher in the low-dose FSH group (9/15, 60%) compared with the high-dose group (2/11, 18%, P=0.051), and ROC curve analysis validated 150 IU as the optimal

Effect: adverse; LBR 2/11 (18%) HD vs 9/15 (60%) LD

Live birth rate per embryo transfer trended higher in the low-dose FSH group (9/15, 60%) compared with the high-dose group (2/11, 18%, P=0.051), and ROC curve analysis validated 150 IU as the optimal

Effect: adverse; LBR 2/11 (18%) HD vs 9/15 (60%) LD

Higher starting dose of FSH with letrozole did not yield significantly more oocytes (13.3 +/- 8.7 vs 12.3 +/- 8.0) or embryos (6.3 +/- 4.7 vs 5.4 +/- 3.8) compared to low-dose FSH, despite producing m

Effect: null; 13.3 vs 12.3 oocytes (HD vs LD)

Higher starting dose of FSH with letrozole did not yield significantly more oocytes (13.3 +/- 8.7 vs 12.3 +/- 8.0) or embryos (6.3 +/- 4.7 vs 5.4 +/- 3.8) compared to low-dose FSH, despite producing m

Effect: null; 13.3 vs 12.3 oocytes (HD vs LD)

Higher starting dose of FSH with letrozole did not yield significantly more oocytes (13.3 +/- 8.7 vs 12.3 +/- 8.0) or embryos (6.3 +/- 4.7 vs 5.4 +/- 3.8) compared to low-dose FSH, despite producing m

Effect: null; 13.3 vs 12.3 oocytes (HD vs LD)

Higher starting dose of FSH with letrozole did not yield significantly more oocytes (13.3 +/- 8.7 vs 12.3 +/- 8.0) or embryos (6.3 +/- 4.7 vs 5.4 +/- 3.8) compared to low-dose FSH, despite producing m

Effect: null; 13.3 vs 12.3 oocytes (HD vs LD)

Higher starting dose of FSH with letrozole did not yield significantly more oocytes (13.3 +/- 8.7 vs 12.3 +/- 8.0) or embryos (6.3 +/- 4.7 vs 5.4 +/- 3.8) compared to low-dose FSH, despite producing m

Effect: null; 13.3 vs 12.3 oocytes (HD vs LD)

Higher starting dose of FSH with letrozole did not yield significantly more oocytes (13.3 +/- 8.7 vs 12.3 +/- 8.0) or embryos (6.3 +/- 4.7 vs 5.4 +/- 3.8) compared to low-dose FSH, despite producing m

Effect: null; 13.3 vs 12.3 oocytes (HD vs LD)

Higher starting dose of FSH with letrozole did not yield significantly more oocytes (13.3 +/- 8.7 vs 12.3 +/- 8.0) or embryos (6.3 +/- 4.7 vs 5.4 +/- 3.8) compared to low-dose FSH, despite producing m

Effect: null; 13.3 vs 12.3 oocytes (HD vs LD)

Higher starting dose of FSH with letrozole did not yield significantly more oocytes (13.3 +/- 8.7 vs 12.3 +/- 8.0) or embryos (6.3 +/- 4.7 vs 5.4 +/- 3.8) compared to low-dose FSH, despite producing m

Effect: null; 13.3 vs 12.3 oocytes (HD vs LD)

Higher starting dose of FSH with letrozole did not yield significantly more oocytes (13.3 +/- 8.7 vs 12.3 +/- 8.0) or embryos (6.3 +/- 4.7 vs 5.4 +/- 3.8) compared to low-dose FSH, despite producing m

Effect: null; 13.3 vs 12.3 oocytes (HD vs LD)

Higher starting dose of FSH with letrozole did not yield significantly more oocytes (13.3 +/- 8.7 vs 12.3 +/- 8.0) or embryos (6.3 +/- 4.7 vs 5.4 +/- 3.8) compared to low-dose FSH, despite producing m

Effect: null; 13.3 vs 12.3 oocytes (HD vs LD)

Higher starting dose of FSH with letrozole did not yield significantly more oocytes (13.3 +/- 8.7 vs 12.3 +/- 8.0) or embryos (6.3 +/- 4.7 vs 5.4 +/- 3.8) compared to low-dose FSH, despite producing m

Effect: null; 13.3 vs 12.3 oocytes (HD vs LD)

Higher starting dose of FSH with letrozole did not yield significantly more oocytes (13.3 +/- 8.7 vs 12.3 +/- 8.0) or embryos (6.3 +/- 4.7 vs 5.4 +/- 3.8) compared to low-dose FSH, despite producing m

Effect: null; 13.3 vs 12.3 oocytes (HD vs LD)

Higher starting dose of FSH with letrozole did not yield significantly more oocytes (13.3 +/- 8.7 vs 12.3 +/- 8.0) or embryos (6.3 +/- 4.7 vs 5.4 +/- 3.8) compared to low-dose FSH, despite producing m

Effect: null; 13.3 vs 12.3 oocytes (HD vs LD)

Higher starting dose of FSH with letrozole did not yield significantly more oocytes (13.3 +/- 8.7 vs 12.3 +/- 8.0) or embryos (6.3 +/- 4.7 vs 5.4 +/- 3.8) compared to low-dose FSH, despite producing m

Effect: null; 13.3 vs 12.3 oocytes (HD vs LD)

Higher starting dose of FSH with letrozole did not yield significantly more oocytes (13.3 +/- 8.7 vs 12.3 +/- 8.0) or embryos (6.3 +/- 4.7 vs 5.4 +/- 3.8) compared to low-dose FSH, despite producing m

Effect: null; 13.3 vs 12.3 oocytes (HD vs LD)

Higher starting dose of FSH with letrozole did not yield significantly more oocytes (13.3 +/- 8.7 vs 12.3 +/- 8.0) or embryos (6.3 +/- 4.7 vs 5.4 +/- 3.8) compared to low-dose FSH, despite producing m

Effect: null; 13.3 vs 12.3 oocytes (HD vs LD)

Higher starting dose of FSH with letrozole did not yield significantly more oocytes (13.3 +/- 8.7 vs 12.3 +/- 8.0) or embryos (6.3 +/- 4.7 vs 5.4 +/- 3.8) compared to low-dose FSH, despite producing m

Effect: null; 13.3 vs 12.3 oocytes (HD vs LD)

Higher starting dose of FSH with letrozole did not yield significantly more oocytes (13.3 +/- 8.7 vs 12.3 +/- 8.0) or embryos (6.3 +/- 4.7 vs 5.4 +/- 3.8) compared to low-dose FSH, despite producing m

Effect: null; 13.3 vs 12.3 oocytes (HD vs LD)

Higher starting dose of FSH with letrozole did not yield significantly more oocytes (13.3 +/- 8.7 vs 12.3 +/- 8.0) or embryos (6.3 +/- 4.7 vs 5.4 +/- 3.8) compared to low-dose FSH, despite producing m

Effect: null; 13.3 vs 12.3 oocytes (HD vs LD)

Higher starting dose of FSH with letrozole did not yield significantly more oocytes (13.3 +/- 8.7 vs 12.3 +/- 8.0) or embryos (6.3 +/- 4.7 vs 5.4 +/- 3.8) compared to low-dose FSH, despite producing m

Effect: null; 13.3 vs 12.3 oocytes (HD vs LD)

Higher starting dose of FSH with letrozole did not yield significantly more oocytes (13.3 +/- 8.7 vs 12.3 +/- 8.0) or embryos (6.3 +/- 4.7 vs 5.4 +/- 3.8) compared to low-dose FSH, despite producing m

Effect: null; 13.3 vs 12.3 oocytes (HD vs LD)

Higher starting dose of FSH with letrozole did not yield significantly more oocytes (13.3 +/- 8.7 vs 12.3 +/- 8.0) or embryos (6.3 +/- 4.7 vs 5.4 +/- 3.8) compared to low-dose FSH, despite producing m

Effect: null; 13.3 vs 12.3 oocytes (HD vs LD)

Higher starting dose of FSH with letrozole did not yield significantly more oocytes (13.3 +/- 8.7 vs 12.3 +/- 8.0) or embryos (6.3 +/- 4.7 vs 5.4 +/- 3.8) compared to low-dose FSH, despite producing m

Effect: null; 13.3 vs 12.3 oocytes (HD vs LD)